Erika Hamilton/LinkedIn
Dec 13, 2024, 16:47
Erika Hamilton presented results from a post-hoc exploratory analysis of the NATALEE trial at SABCS24
TRIO – Translational Research in Oncology shared a post on LinkedIn:
“TRIO News from SABCS2024!
Today (December 11th), Erika Hamilton, presented results from a post-hoc exploratory analysis of the NATALEE (TRIO033) trial, demonstrating that the invasive disease-free survival benefit was maintained among patients who had a dose reduction of ribociclib, and was not impacted by ribociclib relative dose intensity.
These data suggest that it may be possible to implement a dose reduction of ribociclib to 200 mg/day when necessary to manage adverse events, without compromising treatment efficacy for patients with HR+/HER2− early breast cancer.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 03:52
Feb 22, 2025, 03:21
Feb 22, 2025, 03:18
Feb 22, 2025, 02:44
Feb 22, 2025, 02:36
Feb 21, 2025, 15:06